Company profile: Decipher Bio
1.1 - Company Overview
Company description
- Provider of genomic tests for urological cancers, including Decipher Prostate for risk scores to guide treatment decisions and Decipher Bladder for molecular subtyping to aid planning, and the Decipher GRID research platform of whole-transcriptome profiles. Continues to build its GRID database and partners with pharmaceutical companies to identify biomarkers of response to novel therapeutics.
Products and services
- Decipher Bladder: A 219-gene panel-scale genomic test that classifies bladder cancer into molecular subtypes, guiding therapy selection for non-muscle invasive and muscle invasive disease based on precise subtype assignment
- Decipher GRID: A whole-transcriptome-scale research platform with over 200,000 urologic cancer profiles that supports identifying biomarkers of response to novel therapeutics and advances understanding and treatment through comprehensive expression data
- Decipher Prostate: A 22-gene assay-scale genomic test that interrogates prostate cancer tissue to generate risk scores and actionable insights, supporting individualized treatment decision-making based on tumor-specific expression profiles
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Decipher Bio
Senti Bio
HQ: United States
Website
- Description: Provider of synthetic biology-driven cell and gene therapies for cancer, featuring a Gene Circuit platform to program therapies, off-the-shelf CAR-NK cell therapies, and investigational candidates SENTI-202 (logic-gated targeting of CD33/FLT3 for hematologic malignancies incl. AML) and SENTI-301A (for GPC3+ tumors with crIL-15 Gene Circuit), with manufacturing via GeneFab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Senti Bio company profile →
SNIPR Biome
HQ: Denmark
Website
- Description: Provider of CRISPR-based microbial gene therapies that selectively target and eliminate hazardous bacteria without harming beneficial microbes; gut-directed gene therapy via engineered bacteria; CRISPR-Guided Vectors (CGV) for rapid, precise bacterial killing; platforms for in situ therapeutic protein and peptide production; backed by an extensive patent portfolio and research collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SNIPR Biome company profile →
Counsyl
HQ: United States
Website
- Description: Provider of DNA screening for men, women, and their children, focusing on diseases where advanced knowledge can improve health outcomes, whether by changing behavior, pursuing preventative measures, or preparing for what lies ahead.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Counsyl company profile →
SCIEX
HQ: United States
Website
- Description: Provider of mass spectrometry, capillary electrophoresis, ion sources, in vitro diagnostics, HPLC and mobility spectrometry solutions for research, drug discovery and development, clinical research, and food and environmental testing. Portfolio includes Triple Quad, QTRAP, X-Series QTOF, ZenoTOF 7600, Echo MS, and TripleTOF systems supporting qualitative and quantitative analyses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SCIEX company profile →
Enigma Diagnostics
HQ: United Kingdom
Website
- Description: Provider of fully automated molecular testing devices for clinics, plus biological products including protein standards (Purified GFP, Plasmodium falciparum, Canine Heartworm Antigen for veterinary diagnostics), the IFI27 gene biomarker to distinguish influenza from bacterial infections, and the Adapter Chimeric Antigen Receptor preclinical NK-92 cell strategy targeting tumor cells in bone metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enigma Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Decipher Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Decipher Bio
2.2 - Growth funds investing in similar companies to Decipher Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Decipher Bio
4.2 - Public trading comparable groups for Decipher Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →